Loading…
Apimeds Pharmaceuticals US, Inc. is projected to decline to $1.38 by 2027, a -3% move from its current price of $1.42. APUS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.28 | $1.42 | $1.58 | +0.05% |
| May 30 | $1.23 | $1.42 | $1.64 | +0.11% |
| May 31 | $1.19 | $1.42 | $1.70 | +0.16% |
| Jun 1 | $1.16 | $1.42 | $1.75 | +0.21% |
| Jun 2 | $1.13 | $1.42 | $1.79 | +0.26% |
| Jun 3 | $1.11 | $1.42 | $1.83 | +0.32% |
| Jun 4 | $1.08 | $1.43 | $1.87 | +0.37% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.08 | $1.43 | $1.87 | +0.37% |
| Week 2 | $0.9724 | $1.43 | $2.10 | +0.74% |
| Week 3 | $0.8949 | $1.44 | $2.30 | +1.12% |
| Week 4 | $0.8349 | $1.44 | $2.49 | +1.49% |
| Week 5 | $0.7857 | $1.45 | $2.66 | +1.87% |
| Week 6 | $0.744 | $1.45 | $2.83 | +2.24% |
| Week 7 | $0.7078 | $1.46 | $3.00 | +2.62% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Apimeds Pharmaceuticals US, Inc. is a healthcare company that provides digital asset treasury solutions in bitcoin treasury infrastructure. The company operates in Ras al-Khaimah, the United Arab Emirates, and is a subsidiary of Inscobee., Inc.
Apimeds Pharmaceuticals US, Inc. is described by its sector as Healthcare, and its stock trades under the APUS symbol. The description emphasizes a specialization in treasury infrastructure for digital assets, anchored in its corporate structure as a subsidiary.
APUS currently trades at $1.50, with a market capitalization of $18.86M and a ranking of 4964.
The asset sits in the Healthcare category, and its near-term price outlook is framed by a flat to modest path through 2026–2028 before rising more decisively into the 2030s. The year-by-year forecast shows an average price progression toward higher levels, culminating in an average of $6.13 by 2050 and an implied ROI of 308.9%.
Near-term volatility is noted, with the price moving within a defined 30-day range and a current sentiment of NEUTRAL. The forecast highlights substantial upside in later years, supported by a maximum 2050 estimate of $14.11 (avg $6.13) and a max price trajectory that exceeds $3 in several years.
A major floor 85.4% below — a decisive break under it would weaken the trend.
The nearest floor, 8.5% below — buyers have tended to step in here.
The nearest ceiling, 111.3% above — a clean break opens room to run.
A major ceiling 1435.2% above — clearing it would confirm fresh momentum.
Key APUS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of APUS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.43 | Sell | $1.43 | Sell |
| MA 10 | $1.42 | Sell | $1.47 | Sell |
| MA 20 | $1.62 | Sell | $1.76 | Sell |
| MA 50 | $4.06 | Sell | $4.28 | Sell |
| MA 100 | $9.86 | Sell | $8.32 | Sell |
| MA 200 | $15.13 | Sell | $12.63 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.64 | Neutral |
| Stoch RSI (14) | 79.16 | Neutral |
| CCI (20) | -49.43 | Neutral |
| Williams %R (14) | -43.93 | Info |
| MACD (12,26,9) | 0.21 | Buy |
| ROC (12) | -6.21 | Sell |
| Bollinger %B (20,2) | 0.37 | Neutral |
| Stochastic %K (14) | 56.07 | Neutral |
| TRIX (15) | -3.95 | Sell |
| Awesome (5,34) | -0.30 | Sell |
| Ultimate (7,14,28) | 34.92 | Neutral |
| Momentum (10) | 0.08 | Buy |
| Aroon Osc (25) | -24.00 | Sell |
| Hull MA (9) | 1.44 | Sell |
| ADX (14) | 36.02 | Sell |
| ATR (14) | 0.20 | Info |
Near-term technical picture remains NEUTRAL, with RSI14 at 40. The asset’s price is well below both the 50-day and 200-day moving averages, with the SMA50 at $4.66 and the SMA200 at $15.27.
Key near-term support is listed at $1.30 and resistance at $3.00. The 30-day price range runs from $0.73 to $3.08, illustrating wider volatility within the month. The stock shows a high annualized volatility of 200%, underscoring elevated risk around short-term moves.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.30 | $1.42 | $1.87 | 0% | Neutral | |
| $0.9369 | $1.38 | $2.21 | -3% | Neutral | |
| $0.8725 | $1.40 | $2.41 | -2% | Neutral | |
| $1.06 | $1.83 | $3.34 | +29% | Bullish | |
| $1.08 | $1.99 | $3.80 | +40% | Bullish | |
| $1.01 | $1.98 | $3.93 | +39% | Bullish | |
| $0.8839 | $1.85 | $3.80 | +30% | Bullish | |
| $0.7114 | $1.58 | $3.35 | +11% | Neutral | |
| $0.7593 | $1.69 | $3.68 | +19% | Neutral | |
| $0.9076 | $2.02 | $4.52 | +42% | Bullish | |
| $1.09 | $2.43 | $5.60 | +71% | Bullish | |
| $2.44 | $5.42 | $12.47 | +282% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.30 | $1.42 | $1.71 | +0.00% |
| June 2026 | $1.26 | $1.53 | $1.94 | +7.72% |
| July 2026 | $1.20 | $1.49 | $1.95 | -2.58% |
| August 2026 | $1.09 | $1.38 | $1.84 | -7.54% |
| September 2026 | $1.09 | $1.40 | $1.91 | +1.53% |
| October 2026 | $1.10 | $1.43 | $1.99 | +2.41% |
| November 2026 | $1.02 | $1.34 | $1.89 | -6.23% |
| December 2026 | $0.985 | $1.31 | $1.87 | -2.51% |
Click any year to see its month-by-month APUS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Apimeds Pharmaceuticals US, Inc.'s 2026 outlook centres on $1.42, within a $1.30 to $1.87 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, APUS could reach as high as $2.21, with a base case around $1.38 and support toward $0.9369 — roughly -3% from $1.42. A consolidation phase looks the most probable path here.
Expect APUS to range from $0.8725 to $2.41 through 2028. The $1.40 average target implies a -2% move from current prices. That is up +1% on the projected 2027 average. Price action looks broadly range-bound.
The APUS price prediction for 2029 points to an average of $1.83 (low $1.06, high $3.34) — a potential gain of +29% on today's $1.42. Buyers look set to stay in control over this stretch.
In 2030, APUS is projected to trade between $1.08 and $3.80, averaging $1.99 — a potential gain of +40% from today's $1.42. That is up +9% on the projected 2029 average. Momentum favours further upside here.
Apimeds Pharmaceuticals US, Inc.'s 2031 outlook centres on $1.98, within a $1.01 to $3.93 range. That is -1% versus the projected 2030 average. That marks a +39% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, APUS could reach as high as $3.80, with a base case around $1.85 and support toward $0.8839 — roughly +30% from $1.42. Momentum favours further upside here.
Expect APUS to range from $0.7114 to $3.35 through 2033. The $1.58 average target implies a +11% move from current prices. That is -15% versus the projected 2032 average. A consolidation phase looks the most probable path here.
The APUS price prediction for 2034 points to an average of $1.69 (low $0.7593, high $3.68) — a potential gain of +19% on today's $1.42. Price action looks broadly range-bound.
In 2035, APUS is projected to trade between $0.9076 and $4.52, averaging $2.02 — a potential gain of +42% from today's $1.42. That is up +20% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Apimeds Pharmaceuticals US, Inc.'s 2040 outlook centres on $2.43, within a $1.09 to $5.60 range. That is up +21% on the projected 2035 average. That marks a +71% change versus current levels. Momentum favours further upside here.
By 2050, APUS could reach as high as $12.47, with a base case around $5.42 and support toward $2.44 — roughly +282% from $1.42. Buyers look set to stay in control over this stretch.
Investing $1,000 in APUS today (≈ 704.225352 APUS) could be worth
$3,819.3
+$2,819.3 (+282%) by 2050 · US Dollar
Based on the average projected APUS price of $5.42 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in APUSwould be worth at today's price.
$1,000 invested in APUS on May 27, 2025 (≈ 55.555556 APUS) would be worth
$78.89
-$921.11 (-92.1%) today · 0.08× · US Dollar
Based on a APUS entry price of $18 vs. today's $1.42.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.39 | $1,021.58 | +2.2% |
| 1 month ago | $1.88 | $755.32 | -24.5% |
| 3 months ago | $13.6 | $104.41 | -89.6% |
| 6 months ago | $29 | $48.97 | -95.1% |
| 1 year ago | $18 | $78.89 | -92.1% |
| All time (1.0y) ago | $22 | $64.55 | -93.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our APUS forecast.
Our base-case forecast reaches $2.80 around 2050.
Implied market cap at $2.80: $42.26M
The multi-year forecast depicts an upside trajectory with notable shifts in average price across years. In 2026 the average is $1.50, rising modestly through 2028 at $1.51, before a more pronounced ascent begins in 2029 with an average of $2.02 and a 34.5% ROI. The path continues with 2030 at $2.18 (ROI 45%), 2031 at $2.12 (ROI 41%), and 2032 at $2.02 (ROI 34.4%), followed by softer years such as 2033 at $1.72 (ROI 14.8%).
The forecast then re-accelerates: 2034 average $1.84 (ROI 22.4%), 2035 average $2.29 (ROI 52.6%), and a sustained uptrend into 2040 with an average of $2.64 (ROI 76.1%). By 2050, the average price is projected at $6.13 with a max of $14.11 and an ROI of 308.9%, supported by bullish sentiment in 2029–2032 and 2040–2050.
Overall, the long-term view suggests meaningful upside, albeit with periods of neutral or muted returns (for example 2027 at ROI -0.1%). These figures are estimates and not guarantees, and substantial risks remain given the volatility profile.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $2.18, with a minimum of $1.18 and a maximum of $4.16, and an ROI of 45%. Sentiment for 2030 is BULLISH.
Long-term projections indicate a potential upside, with an average price of $6.13 by 2050 and an ROI of 308.9%. However, the near-term outlook includes years with neutral or smaller gains, and the forecast explicitly notes these are estimates, not guarantees.
Yes. The forecast includes yearly maximum values above $3 in several years: 2029 max $3.68, 2030 max $4.16, 2034 max $4.02, 2035 max $5.14, 2040 max $6.07, and 2050 max $14.11.
Current price is $1.50 and market cap is $18.86M.
Near-term sentiment is NEUTRAL with RSI14 at 40. The 50-day and 200-day moving averages are $4.66 and $15.27, respectively. The 30-day range is $0.73–$3.08, with support at $1.30 and resistance at $3.00.
Apimeds Pharmaceuticals US, Inc. Community Discussion
0Share your Apimeds Pharmaceuticals US, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.